Anacor wins big in dermatitis market of many millions
This article was originally published in Scrip
Executive Summary
Anacor Pharmaceuticals jumped 55.9% to close at $131.93 per share on 13 July on positive top-line Phase III results for the atopic dermatitis (AD) drug crisaborole, which could be safer than other topical treatments for millions of patients – mostly children – with mild-to-moderate forms of the skin disease.
You may also be interested in...
Atopic Dermatitis: Ziarco Hopes Oral Therapy Will Trump Injectable Biologics
UK biotech Ziarco’s orally active histamine H4-antagonist shows potential in atopic dermatitis in proof-of-concept studies, and the firm may seek capital for further studies before it is Phase III ready.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.